A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE (NCT06040099)
Phase II Single-Arm Study of Durvalumab and Bevacizumab Following Transarterial Radioembolization Using Yttrium-90 Glass Microspheres (TheraSphere™) in Unresectable Hepatocellular Carcinoma Amenable to Locoregional Therapy
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to measure the efficacy and safety of durvalumab intravenous (IV) solution plus bevacizumab IV solution after transarterial radioembolization (Yttrium 90 glass microspheres TARE) in participants with unresectable hepatocellular carcinoma (HCC) amenable to embolization.
Who can join: Review the eligibility criteria below.
Location: Research Site — Aurora, Colorado
Age range: 18 Years to 130 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (21 Sites)
- Research Site — Aurora, Colorado
- Research Site — Gainesville, Florida
- Research Site — Orlando, Florida
- Research Site — Atlanta, Georgia
- Research Site — Atlanta, Georgia
- Research Site — Chicago, Illinois
- Research Site — Boston, Massachusetts
- Research Site — Detroit, Michigan
- Research Site — St Louis, Missouri
- Research Site — Trenton, New Jersey
- Research Site — Buffalo, New York
- Research Site — New York, New York
- Research Site — Chapel Hill, North Carolina
- Research Site — Columbus, Ohio
- Research Site — Portland, Oregon
- Research Site — Philadelphia, Pennsylvania
- Research Site — Houston, Texas
- Research Site — Charlottesville, Virginia
- Research Site — Seattle, Washington
- Research Site — Milwaukee, Wisconsin
- Research Site — Milwaukee, Wisconsin
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Hepatocellular Carcinoma (HCC)
- Streamlined Resin Y90 Radiation Segmentectomy for Small HCC — Chapel Hill, North Carolina
- Utilize Imaging to Assess Changes in Hepatocellular Carcinoma Perfusion as Potentiated by Intra-Arterial Nitroglycerin — San Francisco, California
- Radiation Therapy Followed by Durvalumab (MEDI4736) and Tremelimumab And Surgery Versus Radiation Therapy Followed by Surgery for Resectable Hepatocellular Carcinoma. — Hamilton, Ontario
- Using Radiotherapy and Immunotherapy to Treat Advanced Liver Cancer Before Transplant — London, Ontario
- Liquid Biopsy for Hepatocellular Carcinoma Molecular Characterization After Y90 — Palo Alto, California
Explore by condition: All Hepatocellular Carcinoma (HCC) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.